|
|
Blood, Vol. 112, Issue 4, 1510-1514, August 15, 2008
Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin
Blood Maniecki et al.
112: 1510
Supplemental materials for: Maniecki et al
Files in this Data Supplement:
- Figure S1. CD163/CD33 coeexpression, and decreased CD163 expression after treatment with gemtuzumab ozogamicin during intravascular hemolysis (patient 2) (JPG, 138 KB)
-
(A) Time-course of C-reactive protein (CRP) concentrations after GO-treatment in relation to episodes of infection (yellow area) and hemolysis (red area). The patient became critically ill during the hemolysis episode (red area) and died 24 months old (72 days after GO treatment). (B) Immunofluorescence confocal laser scanning microscopy revealed the simultaneous presence of CD33 and CD163 on bone marrow macrophages (relapse of acute myeloid leukemia before GO-treatment) (left panel: FITC-conjugated anti-CD33, green immunofluorscence; middle panel: biotin-conjugated anti-CD163/streptavidin-conjugated Alexa-Fluor® 594, red immunofluorescence; right panel: overlay, yellow, marked with white arrowheads) (original magnification ×63). (C) Flow cytometric analysis of CD163 expression on peripheral blood cells during the hemolysis episode in patient 2 (C), compared to a healthy individual (figure 1G). CD163 positive cells were stained with PE (FL2), showing an almost complete depletion of CD163 positive cells (C; right panel).
|
|
